A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of an Adeno-associated Virus Vector VV-14295 Administered Suprachoroidally with the Everads Injector in AdultS with GeographIc Atrophy Secondary to Age-related Macular DegeneratiON (the VISION Study)
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs KRIYA 825 (Primary)
- Indications Dry macular degeneration
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms the VISION Study; VISION
- Sponsors Kriya Therapeutics
- 15 Jan 2025 New trial record